The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist

Biochemical Journal

Volumn 443, Issue 1, 2012, Pages 133-144

  Wilson, Kristy J ^a,b   Mill, Christopher P ^a,c   Gallo, Richard M ^a   Cameron, Elizabeth M ^a   VanBrocklin, Henry ^d   Settleman, Jeffrey ^e,f   Riese II, David J ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUBURN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f GENENTECH INC   (United States)

Author keywords

Antagonist; Epidermal growth factor receptor; ErbB3; ErbB4; Neuregulin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; NEU DIFFERENTIATION FACTOR; NEUREGULIN 2BETA Q43L; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CELL LINE; CELL PROLIFERATION; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NERVE GROWTH FACTORS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84858327908     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20110921     Document Type: Article

References (48)

1. Jones, F. E. (2008) HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J. Mammary Gland Biol. Neoplasia 13, 247-258
2. Hynes, N. E. and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (Pubitemid 40637826)
3. Carpenter, G. (2003) ErbB-4: mechanism of action and biology. Exp. Cell Res. 284, 66-77
4. Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., De Luca, A., Caponigro, F. and Salomon, D. S. (2005) The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets 6, 243-257 (Pubitemid 40667793)
5. Hobbs, S. S., Coffing, S. L., Le, A. T., Cameron, E. M., Williams, E. E., Andrew, M., Blommel, E. N., Hammer, R. P., Chang, H. and Riese, II, D. J. (2002) Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21, 8442-8452 (Pubitemid 36054885)
6. Ponomareva, O. N., Ma, H., Dakour, R., Raabe, T. D., Lai, C. and Rimer, M. (2005) Stimulation of acetylcholine receptor transcription by neuregulin-2 requires an N-box response element and is regulated by alternative splicing. Neuroscience 134, 495-503 (Pubitemid 41111778)
7. Sweeney, C., Lai, C., Riese, II, D. J., Diamonti, A. J., Cantley, L. C. and Carraway, III, K. L. (2000) Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275, 19803-19807 (Pubitemid 30441581)
8. Britten, C. D. (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol. Cancer Ther. 3, 1335-1342
9. Baselga, J. and Hammond, L. A. (2002) HER-targeted tyrosine-kinase inhibitors. Oncology 63 (Suppl. 1), 6-16
10. Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R. and Lemmon, M. A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697
11. Hobbs, S. S., Cameron, E. M., Hammer, R. P., Le, A. T., Gallo, R. M., Blommel, E. N., Coffing, S. L., Chang, H. and Riese, II, D. J. (2004) Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23, 883-893 (Pubitemid 38250933)
12. Wilson, K. J., Mill, C. P., Cameron, E. M., Hobbs, S. S., Hammer, R. P. and Riese, II, D. J. (2007) Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem. Biophys. Res. Commun. 364, 351-357 (Pubitemid 350011072)
13. Plowman, G. D., Green, J. M., Culouscou, J. M., Carlton, G. W., Rothwell, V. M. and Buckley, S. (1993) Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366, 473-475 (Pubitemid 24013882)
14. Riese, II, D. J. and DiMaio, D. (1995) An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 10, 1431-1439
15. Gilmore, J. L., Gallo, R. M. and Riese, D. J. (2006) The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events. Biochem. J. 396, 79-88 (Pubitemid 43764499)
16. Chang, H., Riese, II, D. J., Gilbert, W., Stern, D. F. and McMahan, U. J. (1997) Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387, 509-512 (Pubitemid 27235469)
17. Riese, II, D. J., Bermingham, Y., van Raaij, T. M., Buckley, S., Plowman, G. D. and Stern, D. F. (1996) Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12, 345-353 (Pubitemid 26045205)
18. Riese, D. J., Kim, E. D., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, G. D. and Stern, D. F. (1996) The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem. 271, 20047-20052
19. Riese, II, D. J., Komurasaki, T., Plowman, G. D. and Stern, D. F. (1998) Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem. 273, 11288-11294 (Pubitemid 28204982)
20. Riese, II, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C. and Stern, D. F. (1995) The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15, 5770-5776
21. Penington, D. J., Bryant, I. and Riese, II (2002) Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13, 247-256 (Pubitemid 34755377)
22. Mill, C. P., Zordan, M. D., Rothenberg, S. M., Settleman, J., Leary, J. F. and Riese, II, D. J. (2012) ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer. Genes Cancer, 2, 792-804
23. Hobbs, S. S., Gallo, R. M. and Riese, Jr, D. J. (2005) Phe45 of NRG2β is critical for the affinity of NRG2β for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2β*. Growth Factors 23, 273-283 (Pubitemid 43123824)
24. Reference deleted
25. Mill, C. P., Gettinger, K. L. and Riese, II, D. J. (2011) Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp. Cell Res. 317, 392-404
26. Normanno, N., Bianco, C., De Luca, A. and Salomon, D. (2001) The role of EGF-related peptides in tumor growth. Front. Biosci. 6, 685-707
27. Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A. and Riese, II, D. J. (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol. Ther. 122, 1-8
28. Gallo, R. M. and Riese, II, D. J. (2007) The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. Growth Factors 25, 329-333 (Pubitemid 351194031)
29. Jones, R. B., Gordus, A., Krall, J. A. and MacBeath, G. (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 (Pubitemid 43083134)
30. Kaushansky, A., Gordus, A., Budnik, B. A., Lane, W. S., Rush, J. and MacBeath, G. (2008) System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem. Biol. 15, 808-817
31. Chuu, C. P., Chen, R. Y., Barkinge, J. L., Ciaccio, M. F. and Jones, R. B. (2008) Systems-level analysis of ErbB4 signaling in breast cancer: a laboratory to clinical perspective. Mol. Cancer Res. 6, 885-891
32. Pitfield, S. E., Bryant, I., Penington, D. J., Park, G. and Riese, II, D. J. (2006) Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol. Res. 16, 179-193 (Pubitemid 44744177)
33. VanBrocklin, H. F., Lim, J. K., Coffing, S. L., Hom, D. L., Negash, K., Ono, M. Y., Gilmore, J. L., Bryant, I. and Riese, II, D. J. (2005) Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J. Med. Chem. 48, 7445-7456 (Pubitemid 41743658)
34. Inaba, T. (2004) Cytokine-mediated cell survival. Int. J. Hematol. 80, 210-214
35. Cohen, B. D., Green, J. M., Foy, L. and Fell, H. P. (1996) HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J. Biol. Chem. 271, 4813-4818
36. Elenius, K., Paul, S., Allison, G., Sun, J. and Klagsbrun, M. (1997) Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 16, 1268-1278 (Pubitemid 27136093)
37. Schulze, W. X., Deng, L. and Mann, M. (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008
38. Gallo, R. M., Bryant, I., Fry, R., Williams, E. E. and Riese, II, D. J. (2006) Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem. Biophys. Res. Commun. 349, 372-382 (Pubitemid 44331802)
39. Jones, J. T., Akita, R. W. and Sliwkowski, M. X. (1999) Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447, 227-231 (Pubitemid 29146091)
40. Chung, E., Graves-Deal, R., Franklin, J. L. and Coffey, R. J. (2005) Differential effects of amphiregulin and TGF-α on the morphology of MDCK cells. Exp. Cell Res. 309, 149-160 (Pubitemid 41191231)
41. Willmarth, N. E. and Ethier, S. P. (2006) Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J. Biol. Chem. 281, 37728-37737 (Pubitemid 46042076)
42. Wolff, G. S., Chiang, P. J., Smith, S. M., Romero, R. and Armant, D. R. (2007) Epidermal growth factor-like growth factors prevent apoptosis of alcohol-exposed human placental cytotrophoblast cells. Biol. Reprod. 77, 53-60 (Pubitemid 46986396)
43. Gilmore, J. L., Scott, J. A., Bouizar, Z., Robling, A., Pitfield, S. E., Riese, II, D. J. and Foley, J. (2008) Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res. Treat. 110, 493-505 (Pubitemid 351962595)
44. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci. 28, 390-396
45. Omerovic, J., Puggioni, E. M., Napoletano, S., Visco, V., Fraioli, R., Frati, L., Gulino, A. and Alimandi, M. (2004) Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp. Cell Res. 294, 469-479 (Pubitemid 38326745)
46. Dean-Colomb, W. and Esteva, F. J. (2008) Her2-positive breast cancer: herceptin and beyond. Eur. J. Cancer 44, 2806-2812
47. Hudis, C. A. (2007) Trastuzumab: mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51
48. Stern, K. A., Place, T. L. and Lill, N. L. (2008) EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem. J. 410, 585-594 (Pubitemid 351429029)